^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Lonsurf (trifluridine/tipiracil) (Thymidine phosphorylase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
Excerpt:
...Documented ER positive (10%) and/or PR positive (10%) and HER2 negative metastatic breast cancer 3....
Trial ID:
Source:
Title:
Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.
Published date:
05/25/2023
Excerpt:
Median PFS was 5.7 months (95% CI 3.8 to 8.3) and 9.4 months (95% CI 5.5 to 14.0) respectively in Cohorts A and B. Similar response rates were observed regardless of prior exposure to fluoropyrimidine, with ORR of 19.5% (95% CI 8.8 to 34.9) and 16.1% (95% CI 5.5 to 33.7) in Cohorts A and B, with 6-month clinical benefit rates of 56.1% (95% CI 39.7 to 71.5) and 61.3% (95% CI 42.2 to 78.2) respectively....FTD/TPI showed promising anti-tumor activity with meaningful clinical benefit even among pts with prior exposure to fluoropyrimidines, and has a reasonable toxicity profile with appropriate dose modification.
DOI:
10.1200/JCO.2023.41.16_suppl.1099
Trial ID:
